Table 2.
Age1 | Gender | Precedence | Mode of | Duration of | HBV Genotype2 | Previous | Time without Treatment3 (mo) | Follow-up (mo) | Sampling | |
transmission | infection (yr) | treatment | ||||||||
Pat #1 | 43 | Male | Western Europe | Horizontal | 20 | Undetermined | IFN | 84 | 74 | 8 |
Pat #2 | 30 | Male | Equatorial Ginnea | Unknown | Unknown | A | No | 5 | 4 | |
Pat #3 | 41 | Male | Equatorial Ginnea | Unknown | Unknown | E | No | 2 | 3 | |
Pat #4 | 43 | Male | Eastern Europe | Unknown | Unknown | A | No | 5 | 3 | |
Pat #5 | 45 | Male | Western Europe | IVD | Unknown | A | No | 4 | 4 | |
Pat #6 | 38 | Female | Western Europe | Horizontal | 20 | D | IFN | 36 | 94 | 10 |
Pat #7 | 35 | Female | Western Europe | Horizontal | 25 | E | IFN | 60 | 89 | 13 |
Pat #8 | 55 | Female | Western Europe | Unknown | Unknown | D | No | 17 | 3 | |
Pat #9 | 37 | Male | Equatorial Ginnea | IVD | 22 | A | IFN/ADV | 8 | 77 | 12 |
Pat #10 | 31 | Female | Western Europe | Horizontal | 20 | D | IFN | 12 | 78 | 12 |
Pat #11 | 46 | Male | Western Europe | IVD | 25 | A | No | 53 | 4 | |
Pat #12 | 42 | Male | Western Europe | Unknown | 26 | D | No | 93 | 13 | |
Pat #13 | 45 | Male | Western Europe | Unknown | Unknown | A | No | 42 | 3 | |
Pat #14 | 39 | Male | Western Europe | IVD | 20 | D | No | 41 | 6 | |
Pat #15 | 53 | Male | Western Europe | IVD | 25 | D | No | 89 | 14 | |
Pat #16 | 38 | Female | Equatorial Ginnea | Unknown | Unknown | E | No | 9 | 5 |
Data of age are referred to the first sample analyzed of each patient;
HBV genotype data correspond to the LiPA/PCR-sequencing assays;
Time interval between the end of the previous treatment and the sampling of the first sera included in this study. No statistical differences in the route of infection, duration of infection, or previous antiviral treatment were found between patients infected with the different HBV genotypes. HBV: Hepatitis B virus; IFN: Interferon; ADV: Adefovir; IVD: Intra venous drug user.